Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:24 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD
NCT04759703 · Massachusetts General Hospital · PHASE2/PHASE3 · terminated · last registry update 2025-09-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “An interim analysis indicated that we would need to enroll more subjects than our initial enrollment target, in order to demonstrate a significant treatment effect. Due to these results, we have decided to terminate this protocol.” | – | Registry record, Massachusetts General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DRD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-13Results posted on the registry: University Hospital, Clermont-Ferrand, Dexmedetomidine (NCT03317067)
- 2026-03-09Results posted on the registry: National Cancer Institute (NCI), E7 TCR cells + Aldesleukin (NCT02858310)
- 2026-01-16Also stopped (terminated): Washington University School of Medicine, Ketorolac + Prochlorperazine (NCT06083571)
- 2025-11-24Phase 3 first posted: Mercy Bon Secours Saint Vincent Medical Center, Olanzapine 10 milligram + Haloperidol (NCT07246187)
- 2025-09-25Results posted on the registry: University of Rochester NCORP Research Base, Dexamethasone + Netupitant/Palonosetron Hydrochloride (NCT03367572)
- 2025-09-16Results posted on the registry: Supernus Pharmaceuticals, Inc., SPN-810 + SPN-810 (NCT00626236)
- 2025-08-19Also stopped (withdrawn): United States Naval Medical Center, Portsmouth, prochlorperazine and benadryl IV + Imitrex SubQ, saline IV (NCT00573599)
- 2025-07-29Also stopped (withdrawn): United States Naval Medical Center, Portsmouth, Haloperidol + Metoclopramide 10mg (NCT02098499)
- 2025-06-18Results posted on the registry: University of Michigan Rogel Cancer Center, Ondansetron + Dexamethasone (NCT04503668)
- 2025-06-18Also stopped (terminated): University of Michigan Rogel Cancer Center, Ondansetron + Dexamethasone (NCT04503668)
- 2025-06-12Results posted on the registry: National Cancer Institute (NCI), Etoposide + Rituximab (NCT00001337)
- 2025-06-06Phase 3 first posted: Md. Moktadirul Hoque Shuvo, Tablet Amitriptyline 10 milligrams + Tablet Trifluoperazine 1 milligrams twice daily (NCT07008235)
- 2025-05-21Results posted on the registry: Corewell Health South, Droperidol + Haloperidol (NCT05065567)
- 2025-05-21Also stopped (terminated): Corewell Health South, Droperidol + Haloperidol (NCT05065567)
- 2025-04-01Phase 3 first posted: Wake Forest University Health Sciences, Magnesium + Placebo (NCT06904287)
- 2024-11-29Also stopped (withdrawn): Corewell Health South, Ketorolac + Acetaminophen (NCT03472872)
- 2024-11-20Results posted on the registry: Christine Oryhan, Opioid Anesthetics + Non Opioid Analgesics (NCT04081545)
- 2024-10-01Results posted on the registry: Wake Forest University Health Sciences, Magnesium Sulfate + Metoclopramide 10mg (NCT05967442)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision